7 stories tagged with #erasca, in publish-time order across the WeSearch catalog. Tag pages update as new stories ingest.
⌘ RSS feed for this tag → or search "Erasca"
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS - Morningstar
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.…
Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; Hagens Berman Investigating Intellectual Property Questions Regarding Lead Asset - Morningstar
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.…
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy
Erasca: Strong Data Overshadowed By A Patient Death And A Patent Fight
Erasca is a high-risk, high-reward clinical-stage biotech focused on RAS/MAPK pathway-driven cancers. Click here to read this latest analysis of ERAS stock.…
Erasca, Inc. (ERAS) Discusses Preliminary Phase I Data and Differentiation of Pan-RAS Molecular Glue ERAS-0015 - Slideshow
2026-04-28. The following slide deck was published by Erasca, Inc.…
Erasca, Inc. (ERAS) Discusses Preliminary Phase I Data and Differentiation of Pan-RAS Molecular Glue ERAS-0015 Transcript
Erasca, Inc. (ERAS) Discusses Preliminary Phase I Data and Differentiation of Pan-RAS Molecular Glue ERAS-0015 April 27, 2026 4:30 PM EDTCompany...…